Bidirectional Transfer Study of Polystyrene Nanoparticles across the Placental Barrier in an ex Vivo Human Placental Perfusion Model by Grafmueller, Stefanie et al.
HAL Id: hal-02163367
https://hal.archives-ouvertes.fr/hal-02163367
Submitted on 21 Oct 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Bidirectional Transfer Study of Polystyrene
Nanoparticles across the Placental Barrier in an ex Vivo
Human Placental Perfusion Model
Stefanie Grafmueller, Pius Manser, Liliane Diener, Pierre-André Diener, Xenia
Maeder-Althaus, Lionel Maurizi, Wolfram Jochum, Harald Krug, Tina
Buerki-Thurnherr, Ursula von Mandach, et al.
To cite this version:
Stefanie Grafmueller, Pius Manser, Liliane Diener, Pierre-André Diener, Xenia Maeder-Althaus, et
al.. Bidirectional Transfer Study of Polystyrene Nanoparticles across the Placental Barrier in an ex
Vivo Human Placental Perfusion Model. Environmental Health Perspectives, National Institute of
Environmental Health Sciences, 2015, 123 (12), pp.1280-1286. ￿10.1289/ehp.1409271￿. ￿hal-02163367￿
1280 volume 123 | number 12 | December 2015 • Environmental Health Perspectives
Research A Section 508–conformant HTML version of this article is available at http://dx.doi.org/10.1289/ehp.1409271. 
Introduction
Currently the application of engineered nano­
particles (NP) in industrial and consumer 
products is  increasing continuously. 
Epidemiological as well as in vitro studies have 
shown that engineered, naturally occurring, 
and combustion­derived NPs could have 
adverse health effects in humans (Bell et al. 
2012; Pietroiusti 2012). However, to cause 
damage in vivo, NPs have to cross highly 
protective biological barriers. Besides the 
intestine and skin, the air–blood barrier of 
the lung is an important entry site for NPs. 
Multiple studies have shown that NPs are 
able to cross this protective barrier in vitro 
and in vivo (Geiser et al. 2005; Kreyling 
et al. 2009; Rothen­Rutishauser et al. 2007). 
Furthermore, NPs are applied in various 
medical products such as contrast agents for 
imaging or metal oxide particles for cancer 
therapy (Gupta and Gupta 2005; Rasmussen 
et al. 2010). Because these medical NPs are 
injected, they get direct access to the blood 
circulation. Therefore, it will be increasingly 
important to investigate NP transport across 
internal barriers such as the placental barrier 
between the mother and the unborn child.
The placenta is responsible for the 
supply of nutrients, the removal of waste 
products, and the protection of the fetus 
against harmful substances. It is organized 
in cotyledons, which represent the func­
tional units of the placenta. Each cotyledon 
is formed by a fetal villous tree. Because of 
the extensive division of the villous trees, 
the total exchange surface area at term is 
about 13 m2 (Larsen et al. 1995; Syme et al. 
2004). The maternal blood is released into 
the inter villous space and separated from the 
fetal circulation by the syncytio trophoblast 
layer, some few cyto trophoblast cells, and the 
endothelial cell layer of the fetal capillaries, 
which are surrounded by stromal fibroblasts 
and fetal macrophages. The thickness of this 
barrier decreases during pregnancy to allow 
an increased maternal–fetal exchange at 
late gestational ages (Juch et al. 2013; Syme 
et al. 2004). The syncytio trophoblast layer 
as a key barrier is formed by cyto trophoblast 
cells that fuse during development and 
form a true syncytium without lateral cell 
membranes (Enders and Blankenship 1999). 
The plasma membrane of the syncytio­
trophoblast is highly polarized and consists 
of two membranes. The basal membrane is 
in contact with the villous stroma, which 
surrounds the fetal capillaries, and the brush 
border membrane, with its many microvilli, 
faces the maternal blood stream. The polarity 
of the syncytio trophoblast is based on a 
different repertoire of transport proteins for 
each of these membranes. Furthermore, a 
huge variety of transporters act in both direc­
tions (importer and exporter) to ensure an 
optimal supply with nutrients and an effi­
cient efflux of waste products or harmful 
drugs (Ganapathy et al. 2000). The placental 
transfer of such substances depends on four 
different mechanisms: passive diffusion, 
active transport, phagocytosis/pinocytosis, 
and biotransformation through metabolic 
enzymes (Syme et al. 2004).
Several animal studies showed that 
different NPs such as gold, silica, or titanium 
dioxide can cross the placental barrier, 
and some of them can even impair fetal 
development (Semmler­Behnke et al. 2008; 
Yamashita et al. 2011). However, the placenta 
is the most species­specific organ, and data 
obtained in rodent models cannot be simply 
extrapolated to the human system (Enders 
and Blankenship 1999; Takata and Hirano 
1997). Ex vivo human placental perfusion 
provides an ethically accepted model, close to 
the in vivo situation, to investigate placental 
transport of xeno biotics as well as NPs 
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Background: Nanoparticle exposure in utero might not be a major concern yet, but it could 
become more important with the increasing application of nanomaterials in consumer and medical 
products. Several epidemiologic and in vitro studies have shown that nanoparticles can have 
potential toxic effects. However, nanoparticles also offer the opportunity to develop new therapeutic 
strategies to treat specifically either the pregnant mother or the fetus. Previous studies mainly 
addressed whether nanoparticles are able to cross the placental barrier. However, the transport 
mechanisms underlying nanoparticle translocation across the placenta are still unknown.
oBjectives: In this study we examined which transport mechanisms underlie the placental transfer 
of nanoparticles.
Methods: We used the ex vivo human placental perfusion model to analyze the bidirectional transfer 
of plain and carboxylate modified polystyrene particles in a size range between 50 and 300 nm.
results: We observed that the transport of polystyrene particles in the fetal to maternal direction 
was significantly higher than for the maternal to fetal direction. Regardless of their ability to cross 
the placental barrier and the direction of perfusion, all polystyrene particles accumulated in the 
syncytiotrophoblast of the placental tissue.
conclusions: Our results indicate that the syncytiotrophoblast is the key player in regulating 
nanoparticle transport across the human placenta. The main mechanism underlying this 
translocation is not based on passive diffusion, but is likely to involve an active, energy-dependent 
transport pathway. These findings will be important for reproductive toxicology as well as for 
pharmaceutical engineering of new drug carriers.
citation: Grafmueller S, Manser P, Diener L, Diener PA, Maeder-Althaus X, Maurizi L, 
Jochum W, Krug HF, Buerki-Thurnherr T, von Mandach U, Wick P. 2015. Bidirectional transfer 
study of polystyrene nanoparticles across the placental barrier in an ex vivo human placental 
perfusion model. Environ Health Perspect 123:1280–1286; http://dx.doi.org/10.1289/ehp.1409271
Placental transfer of polystyrene nanoparticles
Environmental Health Perspectives • volume 123 | number 12 | December 2015 1281
(Grafmüller et al. 2013; Malek et al. 2009; 
Panigel et al. 1967; Schneider et al. 1972). 
Using this model, studies have found 25­ and 
50­nm silica particles to be transported across 
the human placental barrier, whereas pegylated 
10­ to 30­nm gold particles were retained in 
the maternal circulation and the placental 
tissue (Myllynen et al. 2008; Poulsen et al. 
2015). Previous work performed by our group 
revealed a size­dependent translocation of poly­
styrene (PS) particles, with placental passage 
of PS particles up to 240 nm in diameter 
(Wick et al. 2010). Although the number of 
in vivo and in vitro studies about placental NP 
transport is increasing (Buerki­Thurnherr et al. 
2012; Saunders 2009), the transport mecha­
nisms for NPs across the placental barrier are 
largely unknown. Knowledge about the route 
of NP transport across the placental barrier 
and the dependency of this transport on the 
physico chemical properties of NPs is a prereq­
uisite for future development of NPs as drug 
carriers to either specifically treat the mother 
without affecting the fetus or to treat placental 
dysfunctions. In addition, a better under­
standing of the translocation of NPs across an 
internal barrier such as the placenta would also 
contribute to a safer design of NPs in general. 
To assess the contribution of the physico­
chemical properties of NPs to placental NP 
transfer and the transport mechanisms under­
lying this process, we performed and analyzed 
bidirectional transfer studies of fluorescently 
labeled PS particles with different sizes and 
surface modifications in the ex vivo human 
placental perfusion model.
Materials and Methods
Particles. We used plain (without functiona­
liza tion) yellow­green–labeled PS beads of 
50 and 240 nm (Spherotech). Yellow­green–
labeled carboxylate­modified (COOH) 50­ 
and 300­nm PS beads were purchased from 
Polysciences Inc.
Particle characterization. We determined 
the zeta potential in 10 mM sodium chloride 
and perfusion medium at pH 6.8–7.2 using a 
Zetasizer NanoZS (Malvern Instruments).
Particle size distribution in double distilled 
(DD) water and perfusion medium (PM) was 
determined by nano particle tracking analysis 
(NTA; NanoSight LM 20 System, software 
version 2.3; NanoSight Ltd.) as described 
previously (Hole et al. 2013). The composi­
tion of the PM is described in Supplemental 
Material, “Ex vivo human placental perfusion 
model.” The DD water and PM were filtered 
through a 0.02­μm Anotop® 25 syringe filter 
(Whatman GmbH) prior to analysis. For each 
particle size, the results were normalized to the 
area under the NP concentration/size curve.
We determined the detection limit of the 
PS beads’ fluorescence by a serial dilution 
(0.02–10 μg/mL) of each PS particle in 
perfusion medium. The detection limit was 
defined as the minimum concentration of PS 
particles in perfusion medium, which showed 
a significant increase in fluorescence intensity 
compared with perfusion medium alone. 
To assess the stability of fluorescence, we 
analyzed the loss of fluorescence intensity 
after incubation of the PS beads in perfu­
sion medium at 37°C for 3, 6, 24, 48, and 
72 hr using a micro plate reader (Biotek 
Synergy HT) with excitation and emission 
wavelengths of 485 and 528 nm. The leakage 
of fluorescence was assessed by measuring 
the fluorescence before and after filtration 
through a 0.1­μm syringe filter at the end of 
the indicated incubation periods.
Cell culture. BeWo cells (b30 clone), a cell 
line derived from human chorio carcinoma, 
were obtained from U. Graf­Hausner 
(Zurich University of Applied Sciences, 
Waedenswil, Switzerland) with permission 
from A.L. Schwartz (Washington University 
School of Medicine, MO, USA). BeWo cells 
cultured in Ham’s F­12K medium (Gibco, 
Thermo Fisher Scientific Inc.) supplemented 
with 1% penicillin­streptomycin and 10% 
fetal calf serum (FCS) at 37°C and 5% carbon 
dioxide (CO2).
MTS viability assay. The in vitro cyto­
toxicity of the different PS beads was tested 
using the MTS viability assay. Twenty­four 
hours before treatment, BeWo cells were 
seeded in a 96­well plate (8,000 cells/well) 
and different concentrations of PS beads were 
applied. Cells without treatment were used 
as the negative control, and 1, 10, 100, and 
1,000 μM cadmium sulfate was used as the 
positive control. After 3 or 24 hr of incuba­
tion at 37°C and 5% CO2, an MTS assay 
(CellTiter96® AQueous One Solution Cell 
Proliferation Assay; Promega) was performed 
according to the manufacturer’s instruc­
tions. Results are presented as the mean 
percentage of the untreated control from 
three  independent experiments.
Viability and functionality, antipyrine 
transfer, and histopathological evaluation of 
placental tissue. Glucose and lactate concen­
trations in the fetal and maternal circuit were 
determined as indicators of tissue viability. 
Production of the placental hormones 
human chorionic gonadotropin and leptin 
were estimated to assess tissue function­
ality. Tissue samples of non perfused and 
perfused placentas were fixed and examined 
by light microscopy. Detailed procedures 
are provided in Supplemental Material, 
“Histopathological evaluation.”
Ex vivo human placental perfusion model. 
The placentas were obtained from uncompli­
cated term pregnancies after cesarean section 
at the Department of Obstetrics, University 
Hospital Zurich and the Kantonsspital 
and the Klinik Stephanshorn in St. Gallen. 
Written informed consent was obtained 
prior to delivery. The project was approved 
by the local ethics committee and performed 
in accordance with the principles of the 
Declaration of Helsinki. The placenta perfu­
sion was performed as described previously 
(Grafmüller et al. 2013; Wick et al. 2010). For 
a brief description see Supplemental Material, 
“Ex vivo human placenta perfusion model.”
Fluorescence microscopy. Unstained 
paraffin sections of nonperfused (negative 
control) and perfused placenta were deparaf­
finized with xylene followed by 100% ethanol. 
The slides were then air­dried and covered 
with VECTASHIELD® Mounting Medium 
containing DAPI (Vector Laboratories) on a 
glass slide; the coverslips were sealed with nail 
polish. The slides were analyzed with a Leica 
DM6000B fluorescence microscope system 
(Leica Microsystems) equipped with a triple 
band pass filter set (DAPI/Spectrum Green/
Spectrum Orange).
Transmission electron microscopy (TEM). 
Particle suspensions, as supplied by the manu­
facturer, were applied onto a carbon­coated 
copper grid and processed for TEM analysis 
(Zeiss 900 TEM; Carl Zeiss MicroImaging). 
Samples from fetal or maternal circulation 
after 1.5–6 hr of perfusion were centrifuged 
twice for 30 min at 25,000 × g at 4°C. The 
pellets were resuspended in DD water and 
processed for TEM analysis as described for 
the particle suspensions.
Statistical analysis. Data are presented 
as mean ± SD of at least three independent 
experiments. Unpaired Student’s t­test was 
performed using GraphPad Prism software, 
version 6 (GraphPad Software). Differences 
were considered statistically significant 
at p < 0.05.
Results
Particle characterization and cytotoxicity 
evaluation. The fluorescently labeled PS beads 
were extensively characterized, and the results 
are summarized in Table 1 and Figure 1. All 
PS particles suspended in 10 mM sodium 
chloride solution were negatively charged, but 
the zeta potential of the COOH PS beads was 
significantly lower than that of plain PS beads 
in the same size range. Analysis of the size 
distribution by nano particle tracking analysis 
confirmed that the plain 50­nm and COOH 
50­nm PS beads were relatively mono disperse 
(Figure 1A,B). However, the plain 240­nm 
and COOH 300­nm PS beads contained an 
additional fraction of smaller beads around 
100 nm, which were not observed to that 
extent in the corresponding TEM micro­
graphs (Figure 1D,F). Furthermore, TEM 
images demonstrated that the plain and 
COOH 50­nm PS beads contained some 
smaller particles of around 20 nm in diameter 
(Figure 1C,E). As expected, the hydrodynamic 
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diameter was higher for all PS beads in perfu­
sion medium compared with those in water 
(Table 1). 
Because a few studies have shown 
a leakage of the fluorescence dye from 
NPs (Pietzonka et al. 2002; Tenuta et al. 
2011), we tested their stability in perfu­
sion medium over a time period of 72 hr 
at 37°C. After 3 hr, fluorescence intensity 
decreased to 75 ± 4% of the initial signal 
for the plain 50­nm, 76 ± 2% for the plain 
240­nm, 83 ± 4% for the COOH 50­nm, 
and 84 ± 5% for the COOH 300­nm PS 
beads, but then remained stable up to 72 hr 
(see Supplemental Material, Figure S1A). 
This slight decrease in fluorescence inten­
sity was not due to a loss of fluorescence 
dye from the particles, as mean leakage of 
the dye was < 0.52% for the plain 240­nm 
and 2.3% for the COOH 300­nm PS beads 
(see Supplemental Material, Figure S1B). 
Filtration of the smaller beads through a 
20­nm syringe filter was attempted, but it 
failed due to the high viscosity of the perfu­
sion medium and the obstruction of the filter. 
Therefore, leakage of the dye could not be 
assessed in these samples.
To confirm the absence of cytotoxic 
effects of the PS beads, an MTS viability 
assay was performed on BeWo cells. These 
cells were used as a model of the syncytio­
trophoblast, which contact the NPs in the 
ex vivo perfusion system first. None of the PS 
particles significantly decreased cell viability, 
even at higher concentrations and longer 
exposure time than those used in the ex vivo 
perfusion experiments (see Supplemental 
Material, Figure S2).
Placental transfer. In a previous study, 
we observed a size­dependent transfer of PS 
beads after 3 hr of ex vivo human placental 
perfusion in the maternal to fetal direc­
tion, with the highest transfer rate for plain 
50­nm PS beads (Wick et al. 2010). In 
the present study we investigated the bidi­
rectional placental transfer of plain 50­ and 
240­nm and COOH 50­ and 300­nm PS 
particles by adding 25 μg/mL PS beads to the 
maternal (M) or to the fetal (F) circulation. 
After 6 hr of perfusion, the concentration of 
all PS beads was increased in reverse direc­
tion (F→M) compared with normal perfu­
sions (M→F) (Figure 2A–D). We observed 
a significant difference in placental transfer 
between normal and reverse perfusions for 
the plain 50­nm (M→F, 13.7 ± 8.4% vs. 
F→M, 23.7 ± 5.8%), the COOH 50­nm 
(M→F, 1.4 ± 0.5% vs. F→M, 7.2 ± 1.3%), 
and COOH 300­nm PS beads (M→F, 
1.2 ± 0.7% vs.  F→M, 5.3 ± 0.5%) 
(Figure 2E). Plain 240­nm PS beads also 
showed a tendency for a higher transfer in 
the reverse direction (M→F, 2.4 ± 0.7% vs. 
F→M, 6.1 ± 4.1%), indicating a generally 
increased placental permeability in the 
F→M direction. In addition, we showed 
an increased translocation of 50­nm plain 
PS beads compared with COOH 50­nm PS 
particles in both directions, indicating that 
the surface charge or modification of NPs 
could also influence placental NP transfer 
(Figure 2A,C,E). For the particles in the size 
range between 240 and 300 nm, a significant 
difference between plain and COOH beads 
was also observed, but only in perfusions 
from the M→F direction (Figure 2B,D,E). 
To ensure that we did not measure placental 
transfer of detached fluorescence dye, we 
wanted to recover the PS beads from the fetal 
(in case of normal perfusions) or the maternal 
(reverse perfusions) perfusates after ex vivo 
perfusion. In TEM micrographs, both large 
(240 and 300 nm) and plain 50­nm PS 
beads were found in the maternal perfusate 
after reverse perfusions, whereas in the fetal 
perfusate after normal perfusions only the 
plain 50­nm PS beads were detected (see 
Supplemental Material, Figure S1C). Transfer 
of the plain 240­nm and both COOH 
beads from the M→F direction was too low 
(< 0.8 μg/mL) for detection by TEM, but still 
within the detection limit of the more sensi­
tive fluorescence measurement. Moreover, 
during ex vivo placental perfusion, a large 
amount of other electron­dense substances 
such as proteins or sugars were released in 
both circulations, which made it especially 
difficult to find the small 50­nm PS beads 
via TEM analysis. Therefore, only the plain 
50­nm PS beads were detectable in TEM 
micrographs due to their high transfer in 
both directions.
As a control for a passively transported 
substance across the placental barrier, we 
added radiolabeled 14C­antipyrine to each 
perfusion. After 4–6 hr, equal concentra­
tions should be reached in both circula­
tions (Challier et al. 1983), and F→M or 
M→F concentration ratios should be 
around 1. This criterion was fulfilled in all 
Table 1. Summary of PS bead characteristics.
NP characteristic
Plain COOH
50 nm 240 nm 50 nm 300 nm
Diameter (nm)a 49 240 42.5 302.7
Diameter in TEM (nm)b 43.7 ± 8 220.5 ± 5.1 44.1 ± 7.1 289.4 ± 10.2
Hydrodynamic diameter in DD water (nm)c 88 ± 79.5 230 ± 65.3 68 ± 19.2 283 ± 85.2
Hydrodynamic diameter in PM (nm)c 104 ± 74.7 273 ± 95.4 114 ± 49.1 359 ± 101.2
Initial no. of particles/mL in PMd 5.45 × 1011 4.24 × 109 5.30 × 1011 1.88 × 109
Particle surface (nm2)/mL in PMd 3.27 × 1015 6.48 × 1014 3.24 × 1015 4.94 × 1014
Detection limit in PM (μg/mL) < 1.25 < 0.63 < 0.078 < 0.078
Zeta potential in 10 mM NaCl (mV)b –19.8 ± 4.0 –20.5 ± 2.7 –34.7 ± 7.1* –55.6 ± 6.1*
Zeta potential in PM (mV)b –11.3 ± 6.5 –13.7 ± 5.8 –11.9 ± 11.2 –13.9 ± 7.4
Abbreviations: DD, double distilled; PM, perfusion medium; TEM, transmission electron microscopy.
aAccording to the manufacturer’s information. bExperimentally determined (mean ± SD). cExperimentally determined 
(mode ± SD). dCalculated values. *p < 0.05 compared with plain beads of the same size. 
Figure 1. Particle size distribution (A,B) and TEM analysis (C–F) of PS beads. Size distribution of plain (A) 
and COOH (B) PS beads was measured in DD water and PM by nanoparticle tracking analysis. (C–F) TEM 
micrographs of plain 50-nm (C), plain 240-nm (D), 50-nm COOH (E), and 300-nm COOH (F) PS beads in 
DD water. Insets show a higher magnification of the PS beads. Arrows indicate an additional fraction 
of smaller PS beads. Abbreviations: COOH, carboxylate-modified; DD, double distilled; PM, perfusion 
medium; PS, polystyrene; TEM, transmission electron microscopy. 
2 μm
500 nm
2 μm
200 nm
500 nm
100 nm
200 nm
500 nm
0 100 200 300 400 500 600
0
0.01
0.02
0.03
N
or
m
al
iz
ed
 v
al
ue
s
N
or
m
al
iz
ed
 v
al
ue
s
50 nm (DD water)
50 nm (PM)
240 nm (DD water)
240 nm (PM)
Plain PS
0 100 200 300 400 500 600
0
0.01
0.02
0.03
Size (nm)
50 nm (DD water)
50 nm (PM)
300 nm (DD water)
300 nm (PM)
COOH PS
Placental transfer of polystyrene nanoparticles
Environmental Health Perspectives • volume 123 | number 12 | December 2015 1283
perfusions, demonstrating that the PS beads 
had no effect on barrier permeability itself 
(see Supplemental Material, Figure S3A,B). 
Of note, the develop ment of the concentra­
tion equilibrium of anti pyrine in reverse 
perfusions was decelerated compared with 
perfusions in the M→F direction (see 
Supplemental Material, Figure S3A,B). 
During the perfusion process, there was no 
influence of the PS beads on viability (glucose 
consumption and lactate production) and 
functionality (human chorionic gonado­
tropin and leptin secretion) of the placenta 
(see Supplemental Material, Figure S3C,D). 
Moreover, in histological tissue sections, we 
identified no visible structural changes to 
the placental tissue after perfusion with or 
without particles (data not shown). 
Despite little transfer of the plain 240­nm 
and COOH 50­nm and 300­nm PS beads in 
both directions, the maternal (normal perfu­
sions) or fetal (reverse perfusions) concentra­
tion of these beads declined (Figure 2B,C,D). 
Fluorescence microscopic images showed that 
these particles accumulated in the placental 
tissue (Figure 3). PS beads were found 
mainly in the syncytio trophoblast layer of 
the placental villi independent of particle 
size, functionalization, or mode of perfusion 
(Figure 3A,B). Unfortunately, a reliable quan­
tification of the PS beads in the tissue based 
on the fluorescence images was not possible 
because resolution is not sufficient to visualize 
single particles and small agglomerates, which 
would lead to an under estimation of NP 
tissue content. Therefore, we calculated the 
theoretical concentration of PS beads in the 
tissue by subtracting the measured concentra­
tion in the fetal and maternal circuit from 
the initial concentration added (Figure 3C). 
After 6 hr of perfusion, the tissue content of 
the PS beads with a higher transfer rate (plain 
50 nm, F→M and M→F; plain 240 nm, 
F→M; COOH 300 nm, F→M) was signifi­
cantly lower compared with the PS beads 
with low placental transfer (COOH 50 nm, 
M→F and F→M; plain 240 nm, M→F; 
COOH 300 nm, M→F) (Figure 3C). 
Discussion
In this study we observed a bidirec tional 
transfer of plain and COOH PS beads up 
to a size of 300 nm using the ex vivo human 
placental perfusion model. Placental transport 
was increased in reverse perfusions from the 
fetal to the maternal side, indicating that there 
are different transport mechanisms for PS 
particles on the fetal and maternal sides of the 
human placenta. Although transport in the 
reverse direction is physiologically not relevant 
regarding in vivo exposure to NPs, because it 
occurs only in the maternal circulation, reverse 
ex vivo placental perfusion is a common 
method to evaluate the mode of transport 
of many drugs across the human placenta 
(Nanovskaya et al. 2012; Nekhayeva et al. 
2005; Sudhakaran et al. 2005). For example, 
a study about bidirectional placental transfer 
of anti biotics revealed that telavancin had a 
higher placental transfer in the reverse direc­
tion, suggesting that a translocation occurred 
by means other than passive diffusion and 
indicating that specific transporters may be 
involved (Nanovskaya et al. 2012). However, 
it is rather unlikely that NPs, in general, are 
transported via such transporters across the 
placenta (Menezes et al. 2011). Nevertheless, 
our results demonstrate that passive diffu­
sion is not the key mechanism under lying 
placental translocation of PS particles because 
concentration equilibrium was not achieved 
after 4–6 hr compared with the passively 
transported antipyrine. According to Fick’s 
law, diffusion of a substance depends mainly 
on the permeability of the membrane for the 
specific substance, the concentration gradient 
across the membrane, and the membrane 
surface area. In the present study, placental 
transfer kinetics of anti pyrine from the F→M 
direction was significantly delayed compared 
with the M→F direction; this was likely due 
to the lower exchange surface on the fetal 
side (i.e., the inner surface of the fetal capil­
laries compared with the very large brush 
border membrane of the syncytio trophoblast 
on the maternal side) and the reduced fetal 
perfusion flow (3–4 mL/min compared 
with 12 mL/min for the maternal circuit) 
(Challier et al. 1983). Thus, NP transfer 
in the reverse direction should be reduced 
if it is based predominantly on a passive 
transport mechanism. 
Figure 2. Perfusion profiles and transfer rates of PS beads during ex vivo human placental perfusion. 
Transplacental transport of plain (A,B) and COOH (C,D) PS beads over 6 hr either from maternal to fetal 
(M to F; normal) or from F to M (reverse) circulation. Beads (25 μg/mL) were added to the perfusions, and 
the concentration of particles was determined by fluorescence measurement at several time points. Data 
represent the particle concentration (mean ± SD) of at least three independent experiments. (E) Transfer 
of PS beads calculated after 6 hr of perfusion. Data are expressed as the percentage of the initial concen-
tration of PS beads added (mean ± SD) of at least three independent experiments. Abbreviations: COOH, 
carboxylate-modified; PS, polystyrene. 
*p < 0.05. **p < 0.01. ***p < 0.001.
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In contrast to such an expectation, we 
observed an augmented transfer in the F→M 
direction (compared with M→F) of PS 
particles independent of their physico chemical 
properties, suggesting an energy­dependent 
transport mechanism for PS particle transloca­
tion across the human placenta. Phagocytosis 
is one example of an energy­dependent 
mechanism proposed for NP uptake into 
cells, especially in phagocytes (Jud et al. 
2013). Primary human macrophages have 
been shown to engulf  COOH PS beads via 
this pathway, whereas THP­1 cells, a human 
monocytic leukemia cell line, use an endo­
cytosis pathway (Lunov et al. 2011). During 
phagocytosis, vesicles with a diameter > 0.5 μm 
are formed, whereas the diameter of endo­
cytotic vesicles is considerably smaller (Aderem 
and Underhill 1999). Caveolin­coated vesicles 
are defined as membrane invaginations with 
a diameter of 60–80 nm, and vesicles arising 
from clathrin­dependent endocytosis have a 
diameter of approximately 120–150 nm in 
human epithelial cells (McMahon and Boucrot 
2011; Parton and Simons 2007). A study using 
specific transport pathway inhibitors revealed 
that A549 cells, a human alveolar epithelial 
cell line, take up gold NPs with a diameter of 
15 nm mainly by endo cytosis (Brandenberger 
et al. 2010). Moreover, endo cytosis and trans­
cytosis have also been proposed as the most 
common transport mechanisms for NPs at the 
blood–brain barrier (Kreuter 2014).
Most of the studies about NP uptake 
mechanism have been performed on 
non polarized cells or cell lines, which do not 
resemble a typical polarized barrier such as the 
placental syncytiotrophoblast. The different 
membrane properties and receptor reper­
toires on the apical and basal sides may allow 
different transport mechanisms depending on 
the site of exposure. So far, most groups have 
observed NP uptake in the syncytio trophblast 
after ex vivo human placental perfusion even if 
NP translocation to the fetal circulation was 
absent or below the detection limit (Menjoge 
et al. 2011; Myllynen et al. 2008; Poulsen 
et al. 2015). We also observed that most of the 
PS particles accumulated predominantly in 
the syncytiotrophoblast layer, which indicates 
that the syncytium is a major determinant of 
NP transfer. Besides the syncytiotrophoblast, 
the endothelial cells of the fetal capillaries 
are also part of the placental barrier. These 
cells contribute to the barrier function and 
act primarily as a molecular sieve for larger 
hydrophilic molecules (Firth and Leach 1996). 
However, to evaluate the definite contribu­
tion of the fetal endothelium to placental NP 
transfer, in vitro co­culture models including 
trophoblasts, as well as endothelial cells, are 
necessary and currently under development 
(Levkovitz et al. 2013).
Nanoparticle uptake into cells also 
depends on the physico chemical properties 
of the materials (Lunov et al. 2011). We 
demonstrated that COOH PS beads were 
transferred across the placenta in significantly 
lower amounts than plain particles. The 
COOH PS beads had a lower zeta poten­
tial than the plain beads, indicating that the 
surface charge of NPs can have an impact 
on placental transfer. Indeed, such a surface 
charge–dependent placental translocation has 
been demonstrated in pregnant rats, where 
Figure 3. Localization (A,B) and quantification (C) of PS beads in the placental tissue. (A) Fluorescence microscope images of placental tissue after 6 hr of 
perfusion in normal (M to F) and reverse (F to M) directions with plain 50-nm, plain 240-nm, COOH 50-nm, and COOH 300-nm PS beads (green). Nuclei were 
stained with DAPI (blue). (B) Fluorescence microscope images of placental tissue before and after control perfusions without particles. (C) Theoretical NP tissue 
content after 6 hr of perfusion. Values represent the percentage of initially added PS beads remaining after subtraction of the PS fractions detected in fetal and 
maternal circuits after 6 hr (mean ± SD of at least three independent experiments). Abbreviations: COOH, carboxylate-modified; FC, fetal capillary; MB, maternal 
blood space; NP, nanoparticles; PS, polystyrene; S, stroma; ST, syncytiotrophoblast; TEM, transmission electron microscopy. 
*p < 0.05. ***p < 0.001.
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amine­modified PS beads showed a stronger 
trans location than COOH PS beads (Tian 
et al. 2009). Similar observations have been 
made with NPs at other biological barriers. 
The accumulation of negatively charged gold 
NPs in secondary organs after oral exposure in 
rats was higher than that of positively charged 
particles (Schleh et al. 2012). Furthermore, 
studies of NP uptake at the air–blood barrier 
revealed that the surface charge of NPs below 
a size threshold of 34 nm is the most critical 
factor for translocation (Choi et al. 2010). 
Differently charged NPs acquire a distinct 
protein corona after contact with serum or 
biological fluids (Hirsch et al. 2013; Lundqvist 
et al. 2008; Monopoli et al. 2011). 
The protein corona can influence the 
biological fate of NPs through alteration 
of their hydro dynamic diameter or surface 
properties. In addition, serum proteins can 
also directly influence the uptake mechanism 
of NPs by binding to their specific recep­
tors on the cell surface, thereby mediating 
endo cytosis (Monopoli et al. 2012). Several 
groups observed that the albumin concen­
tration in the perfusion medium determines 
the transplacental transfer of several drugs in 
the ex vivo human placental perfusion model 
(Mathiesen et al. 2009; Nanovskaya et al. 
2008). The perfusion medium used in our 
study was supplemented with albumin only, 
not with complete serum. However, many 
other proteins are produced by placental cells 
during perfusion and are released into the 
circulation, where they can make contact with 
the PS beads. Interestingly, many hormones 
produced in the placenta are secreted asym­
metrically into the maternal and fetal circu­
lation (Linnemann et al. 2000; Malek et al. 
2001). Therefore, adsorption of different 
proteins in fetal and maternal circulation may 
also provide an explanation for the differential 
transport in normal and reverse perfusions 
in our study. To corroborate this hypothesis, 
further studies are needed that examine both 
a broad variety of differently charged NPs and 
the composition of the NP protein corona. 
Studies using the ex vivo human placental 
perfusion model are limited to a few hours 
of perfusion due to tissue degradation 
(Panigel et al. 1967; Schneider et al. 1972) 
and only reflect placental transport at late 
pregnancy. To assess long­term effects of NP 
exposure and transport during early stages 
of pregnancy, when the placental barrier is 
much thicker (Nikitina et al. 2015), in vitro 
studies are indispensable. In addition, in vitro 
studies would allow a higher throughput 
than ex vivo perfusions. Thus, involvement 
of specific transport pathways could be 
tested first in vitro and then be subsequently 
confirmed in the ex vivo placental perfusion 
model, which is more similar to the in vivo 
situation. Overall, development of more 
advanced and carefully validated in vitro 
models, which include flow cell systems and 
several placental cell types, are expected to 
lead to a better understanding of NP trans­
port mechanisms across the placental barrier 
and their dependence on the physico chemical 
 properties of NPs.
Conclusions
To our knowledge, this is the first study to 
investigate the transport mechanism of NPs 
by examining the bidirectional transfer of PS 
particles in the ex vivo human placental perfu­
sion model. We demonstrated an increased 
transfer of PS beads in reverse perfusions 
(F→M direction) and an accumulation of 
PS beads in the syncytio trophoblast layer of 
the placental tissue. Based on our findings, 
we can exclude a transfer via passive diffu­
sion. We propose an energy­dependent 
placental translocation pathway with the 
polarized syncytio trophoblast as the main 
contributor to NP transfer in the placenta. 
For the develop ment and the safe use of NPs 
in nanomedicine, transport mechanisms of 
NPs across the placental barrier need to be 
determined precisely in further studies.
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